The challenge we all have is managing expectations. The
The challenge we all have is managing expectations. The stock price used to be more resilient. It really moved based on good news, or expectations of good news.
For example, I remember back in 2013 when it went from .03 cents to .09 cents based on Maart Sarma getting a grant to study MANF on diabetes. After everyone realized the study would take some time and nothing more was imminent, the pps went back down to .045 cents after a few weeks, but at least it showed movement based on news.
Then in January of 2014 it went from .06 cents to .137 cents based on hopes of a Lympro partner, but when that didn't happen it went back down to .07 cents.
Then again in June of 2014 the stock went from .07 cents all the way up to .193 cents based on hopes the Lympro data would be great and a partnership would follow....but when it didn't happen, we went down to .07 cents again, where we have more or less stayed for 6 months.
The stock no longer shows movement based on good news anymore, or even expectations of good news. (The Boy Who Cried Wolf Syndrome)
This isn't a bad thing. It means that both management and shareholders are becoming more realistic about the stock. In the end it is usually infusion of MONEY that gets a small Bio-tech penny stock moving: revenue, JV money, grants, etc. Once the movement upward is sustainable, they then up list and institutional investors help grow the company.
Hard to say when MONEY will transform us. MJFF could supply a nice grant for Eltoprazine and that might be nice. Some Partner could step in on the Diagnostic Company. The Congressmen Gerald spoke with about Lympro in that article yesterday could mean funding is coming. LymPro should start making some sales. The MS diagnostic is only 3 or 4 months away from actual revenue. Some combination of these things will happen in the coming weeks and months and we'll get out of this "The Boy That Cried Wolf Syndrome" and the pps will be more responsive to news again. We're going to soar, but MONEY must come in first to light the fuse!!
Amarantus Bioscience Holdings (AMBS) Stock Research Links
Scroll down for more posts ▼
Top 10 Most Recent News Articles
Adapting Space or Adapting Business? Here's the thing that keeps popping up in commercial real estate: tenant improvement construction. This isn't just modifying a structure—it's about rethinking how businesses operate within a certain space. The HelloNation article gives you the lowdown straight from Bradley Quakenbush of White Oak Commercial Group. When businesses...
Continue Reading
A Haunted Wash Awaits Miami Drivers Picture this: you're cruising down West Flagler on a regular Wednesday evening, but tonight, you're not just rolling in for a rinse. Nope, this Wednesday night, the wash tunnel at El Car Wash gets downright spooky. It's getting a haunted house makeover with scare actors from the House of Horror. When a Car Wash Becomes a Haunted...
Continue Reading
Class Action Kickoff: Lincoln's Educational Curveball No one fancies home runs when the ball’s out of sight, and that’s probably how some investors in Lincoln Educational Services Corporation (NASDAQ: LINC) are feeling right now. A group of shareholders has pulled back the curtain on what they believe are more than just administrative hiccups—allegations of...
Continue Reading
Ever wonder how the cogs in this massive machine called franchising keep turning? It's folks like Richard Huffman who step up to the plate, and his recent election to the International Franchise Association (IFA) Board of Directors is worth a second glance. Huffman: A Franchise Veteran Now, Huffman isn't some rookie in the world of franchising. You see, back in '94, he...
Continue Reading
The DOCS Predicament: Investors Facing Class Action Doximity, Inc., trading as NYSE:DOCS, finds itself in hot water again as shareholders gear up for a legal skirmish over alleged securities fraud. Schall, Brown & Schwartz LLP, the firm rallying the shareholders, has fired the opening salvo, pointing fingers at Doximity for cooking the books about their Newsfeed’s...
Continue Reading
The Real Elbow Grease Behind Cabin Management Ever imagined what it’d take to keep a vacation rental cabin running like a tight ship? Well, Nathan Fitts breaks it down real clear-like. The guy's seen it all in Blue Ridge, Georgia, which isn't just about scenic views—there's serious business brewing behind that cabin charm. More Than Just Fluffing Pillows Turns out,...
Continue Reading
Accreditations That Matter It's not every day a treatment facility pops its head up with credentials that weigh like a ton of bricks. New Chapter Recovery in New Jersey just snagged two heavy hitters: Joint Commission accreditation and LegitScript certification. These badges don’t just glimmer for show; they’re the market's assurance against empty promises—an...
Continue Reading
Plata Rocks the Boat with Rapid Revenue Growth When a digital bank like Plata rakes in $1 billion in Annual Recurring Revenue (ARR) within just 3.5 years, you can't just shrug it off. That's blazing fast by any standard, especially for a financial institution. Emerging from Mexico, this bank's rocket-like ascent is flinging the doors wide open for what's possible in the...
Continue Reading
A Game-Changer in Proteomics Now ain't this something—eGlint just scooped up the 2026 BioTools Innovator Grand Prize, waving a big ol' $250,000 check around and claiming the biotech spotlight with their swift-moving ProteoNex™ platform. Forget about sticking samples through sluggish labs and waiting an eternity; eGlint's tech is flipping the switch, serving up protein...
Continue Reading
Crucial Insights from the Convergence Conference Rich with intrigue, the privacy and AI governance game just upped its stakes. If there ever was a time to listen closely, it's now, people. With over 150 laws sprouting up faster than weeds, businesses are getting squeezed to keep their artificial ducks in a row. Last month over in New York, some big names in law and...
Continue Reading
Top 5 Most Recently Viewed Articles
David Deamer's Remarkable Recognition Renowned scientist David Deamer, Ph.D., has been honored for his extraordinary contributions to biomolecular technologies. This distinguished recognition comes from the Association of Biomolecular Resource Facilities (ABRF), which named Deamer the recipient of their prestigious ABRF Award, an accolade given to those who have made...
Continue Reading
Qualcomm's Stock Performance Qualcomm Inc. (NASDAQ: QCOM) is experiencing a decline in its stock price as recent analyst evaluations raise concerns regarding its future earnings potential. This downward trend follows, in part, an important downgrade by analysts highlighting challenges ahead for the company. Understanding the Downgrade KeyBanc analyst John Vinh made...
Continue Reading
Intensity Therapeutics Regains Nasdaq Compliance Intensity Therapeutics, Inc. (NASDAQ: INTS) is excited to share significant news regarding its compliance status with Nasdaq's minimum stockholders' equity requirement. The company, committed to developing innovative intratumoral cancer therapies, recently received a notification from the Listing Qualifications Staff of The...
Continue Reading
Strong Financial Performance from Resmed Inc. Resmed Inc. (NYSE: RMD, ASX: RMD) has announced impressive financial results for its latest quarter, indicating clear growth and sustained demand for its innovative health solutions in sleep and breathing fields. The company's revenue saw an encouraging year-over-year increase of 8%, rising to $1.3 billion. Notably, this...
Continue Reading
Fangzhou Brings Otsuka's Ponatinib to Patients Fangzhou Inc., a leader in innovative healthcare solutions, has announced the launch of Otsuka Pharmaceutical's third-generation tyrosine kinase inhibitor. This groundbreaking treatment is known as Ponatinib, also branded as Iclusig® and is now accessible through Fangzhou's online platform. This offering significantly...
Continue Reading